Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden.

Summary, in English

This study aimed to assess the costs and benefits of three alternative second-line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail to reach glycated hemoglobin (HbA1c) ≤ 7% with metformin treatment alone: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and neutral protamine Hagedorn (NPH) insulin.

• Författare: Aliasghar Ahmad Kiadaliri; Ulf Gerdtham; Bjorn Eliasson; Katarina Steen Carlsson
• Avdelning/ar: Hälsoekonomi; EpiHealth: Epidemiology for Health
• Publiceringsår: 2014
• Språk: Engelska
• Sidor: 591-607
• Publikation/Tidskrift/Serie: Diabetes therapy : research, treatment and education of diabetes and related disorders
• Volym: 5
• Issue: 2
• Fulltext: - 1 MB; Download statistics
• Länkar: http://www.ncbi.nlm.nih.gov/pubmed/25213800?dopt=Abstract; http://dx.doi.org/10.1007/s13300-014-0080-0
• Dokumenttyp: Artikel i tidskrift
• Förlag: Springer
• Ämne: Endocrinology and Diabetes
• Status: Published
• Forskningsgrupp: Health Economics
• ISBN/ISSN/Övrigt: ISSN: 1869-6953